GlobeNewswire

Immunicum AB (publ) meddelar att ett abstrakt publicerats för presentation på årets virtuella ESMO-kongress

Dela

Pressmeddelande

14 september 2020

Immunicum AB (publ) meddelar att ett abstrakt publicerats för presentation på årets virtuella ESMO-kongress

Immunicum AB (publ; IMMU.ST) meddelar idag att bolaget kommer att presentera prekliniska data under en posterpresentation på årets ESMO-kongress (ESMO Virtual Congress 2020). Bolagets huvudkandidat, ilixadencel, har studerats i kombination med olika cancerbehandlingar och immunterapier inklusive anti-VEGF, anti-PD1 och anti-CTLA4. De data som kommer att presenteras på ESMO är en vidare utveckling av de prekliniska resultat som presenterades i oktober förra året. Immunicum kommer att publicera ett pressmeddelande och postern, inklusive ytterligare resultat utöver vad som ingår i abstraktet, på bolagets hemsida. Det sker torsdagen den 17 september klockan 09:00 CET.

Abstrakt från ESMO-kongressen publicerades idag på kongressens hemsida: https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Information kring presentationen:

Titel:                              Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) in combination with anti-CTLA-4 treatment induce     
                                      complete tumor responses and anti-tumor immune memory in a mouse tumor model
Abstraktnummer:        Abstract 3081
Session:                       Developmental Therapeutics
Posterpublicering:       17 september 2020, kl. 09:00 CET/03:00 EDT
Presentatör:                Alex Karlsson-Parra, MD, PhD, forskningschef på Immunicum

Om ilixadencel

Cellterapiprodukten ilixadencel är en immunaktiverare som är lagringsbar (”off-the-shelf”) och som utvecklats för behandling av solida tumörer. Den aktiva beståndsdelen är aktiverade dendritceller som tas från friska blodgivare. Injektion med dessa celler intratumoralt ger upphov till en inflammatorisk reaktion som i sin tur leder till en tumörspecifik aktivering av patientens cytotoxiska T-celler. Hittills har ilixadencel testats i en rad kliniska prövningar i olika solida tumörindikationer inklusive metastaserande njurcancer (mRCC), hepatocellulärt karcinom (HCC), gastrointestinala stromala tumörer (GIST) och i kombination med flera standardbehandlingar av cancer som tyrosinkinashämmare Sutent® (sunitinib) och Stivarga® (regorafenib) och checkpointhämmaren Keytruda® (pembrolizumab). Ilixadencel har genomgående upprätthållit en positiv säkerhets- och tolerabilitetsprofil och visat initiala tecken på effekt, som visats i den randomiserade fas II MERECA-studien. Ilixadencel går för närvarande mot klinisk utveckling i sen fas.

FÖR MER INFORMATION, VÄNLIGEN KONTAKTA:

Alex Karlsson-Parra, forskningschef, Immunicum
Telefon: +46 8 732 8400
E-post: info@immunicum.com

Sijme Zeilemaker, COO, Immunicum
Telefon: +46 8 732 8400
E-post: info@immunicum.com

Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet.  Bolagets huvudprodukt ilixadencel, som består av pro-inflammatoriska allogena dendritiska celler, har potentialen att bli en grundkomponent i moderna kombinationsbehandlingar i flertalet solida tumörindikationer. Immunicum har utvärderat ilixadencel i flera olika kliniska studier, inklusive den nyligen avslutade explorativa fas II-studien MERECA inom njurcancer och bolaget går för närvarande mot klinisk utveckling i sen fas.  Immunicum är grundat och baserat i Sverige och är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Golar LNG Partners LP: Q3 2020 results presentation24.11.2020 16:11:33 CETPress release

Golar LNG Partners LP 3rd Quarter 2020 results will be released before the NASDAQ opens on Monday, November 30, 2020. In connection with this a webcast presentation will be held at 4:30 P.M (London Time) on Monday, November 30, 2020. The presentation will be available to download from the Investor Relations section at www.golarlngpartners.com Due to ongoing high levels of demand for their services, our platform providers highly recommended that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call dial-in information below. Call handling may take longer than usual. You should therefore dial in 10-15 minutes prior to the start time. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant. a. Listen-only l

DFDS A/S: DANISH DEFENCE AND DFDS ENTER INTO NEW AGREEMENT24.11.2020 15:30:13 CETPress release

Investor news Today, DFDS and the Joint Movement and Transport Organisation (JMTO), which provides strategic transport for Danish military missions, have entered into a new agreement. According to the agreement, a total of seven freight ferries (ro-ro) will be made available for the maritime transport of military materiel and equipment in connection with NATO preparedness, participation in military exercises and operations, and humanitarian crises. The agreement, concluded after the task went out to public tender, replaces an earlier agreement between the Danish Defence and DFDS, and runs for six years. On a day-to-day basis, the ferries will be deployed on DFDS’ routes, and will be made available to the military when and to the extent requested by the Danish Defence. The agreement is also linked to the ARK project, a Danish-German cooperation project, which ensures access to and availability of maritime transport capacity for Danish and German defences in accordance with the nations’

FORSVARET OG DFDS INDGÅR NY AFTALE24.11.2020 15:30:13 CETpressemeddelelse

Investor news DFDS og Joint Movement and Transportation Organisation (JMTO), som leverer strategisk transport i forbindelse med danske militære opgaver, har i dag indgået en ny aftale.I alt syv fragtfærger (ro-ro) stilles ifølge aftalen til rådighed for søtransport af militært materiel og udstyr i forbindelse med NATO-beredskabet, deltagelse i militære øvelser og operationer samt humanitære kriser. Aftalen, der er indgået efter et offentligt udbud af opgaven, erstatter en tidligere aftale mellem forsvaret og DFDS, og løber i seks år. I det daglige vil færgerne være indsat på DFDS’ ruter og blive stillet til rådighed for militæret, når og i det omfang forsvaret anmoder om det. Aftalen er desuden knyttet til ARK-projektet, et dansk-tysk samarbejde, der sikrer dansk og tysk forsvar adgang til og rådighed over kapacitet til søtransport i henhold til nationernes egne forpligtelser over for NATO. Kontakt Torben Carlsen, CEO +45 33 42 3201 Karina Deacon, CFO +45 33 42 3342 Søren Brøndholt Nie

Cypress Development Reports Further Positive Metallurgical Results from Clayton Valley Lithium Project in Nevada24.11.2020 14:00:00 CETPress release

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”) reports the completion of additional metallurgical testing following the positive Prefeasibility Study (PFS) published on the Company’s 100%-owned Clayton Valley Lithium Project in Nevada, USA. The testing was conducted at Continental Metallurgical Services in Montana and NORAM Engineering in British Columbia, in preparation for the Company’s pilot plant program as outlined in the PFS. Highlights Testing resulted in 80.2% extraction of lithium when a sodium chloride solution was used instead of distilled water in leaching claystone under Cypress’ sulfuric acid leach process. Lithium in the resulting leach solution was successfully concentrated at levels comparable to the PFS with limited interference by chlorides and other minerals present. The ability to tolerate high chloride levels in the process is significant because it al

RevoluGROUP Canada Inc. RevoluSEND Extends Remittance Reach with Thunes24.11.2020 14:00:00 CETPress release

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt:IJA2) (the "Company") is pleased to announce that RevoluPAY EP S.L. has signed a Definitive Agreement ("DA") with Thunes on November 23rd, 2020. The DA, approved between RevoluPAY CEO Alfredo Manresa and Adrien Antoni, Director of Thunes, permits, with immediate effect, RevoluPAY® family remittances at over 9,000 collection partner agencies offered by www.thunes.com in +100 countries. The parties have agreed upon delivery commissions payable to Thunes, independent of the amount sent and per individual beneficiary delivery and origination via RevoluPAY. The Scope of The Thunes Accord Today's agreement with Thunes expands the reach of the Company's remittance vertical RevoluSEND into supplementary countries, adding 38 nations previously unavailable, most notably crucial high volume remittance markets (Denoted Bold). The addition of Brazil, Chile, and Haiti in South America. As

Olainfarm invites to Third Quarter 2020 Investor Conference Webinar24.11.2020 13:54:00 CETPress release

JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on December 2, 2020 at 04:00 PM (EET). To join the webinar please follow the instructions below. Webinar will be hosted by the members of the management board Zane Kotāne un Elena Bushberg. The presentation will be held in English. During the webinar JSC Olainfarm representatives will inform about the recent performance of the company, sales activities in Russia and financial results of third quarter of 2020 and 9 months of 2020. After the presentation investors are welcome to ask questions. Due to the limited webinar time please send in your questions until December 1 to e-mail: marta.muizniece@nasdaq.com. What is a webinar? Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask qu